Aegerion Pharmaceuticals Inc., a Bridgewater, N.J.-based drug company focused on cardiovascular and metabolic diseases, has filed for an $86.25 million IPO. This is the company’s second stab at the public markets, having filed for an $86.25 million IPO this past January that it later pulled due to “market conditions.”
It plans to trade on the Nasdaq under ticker symbol AEGR, with Piper Jaffray and Thomas Weisel serving as co-lead underwriters. Prior underwriter Lehman Brothers is not listed on the new filing.
Aegerion has raised around $40 million in total VC funding, including a recent $17.5 million Series B infusion. Shareholders include Index Ventures (20% pre-IPO stake), Advent International (18.5%), Alta Partners (17.3%), Scheer & Co. (8.9%) andMVM Life Science Partners (6.1%). www.aegerion.com
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.